Elicio Therapeutics, Inc. (ELTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Elicio Therapeutics, Inc. on September 14, 2026. The report announces the scheduling of the Company's 2026 Annual Meeting of Stockholders and establishes deadlines for shareholder proposals and director nominations.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and does not contain financial performance data.
Material Changes
The primary material event is the rescheduling of the 2026 Annual Meeting of Stockholders to November 12, 2026. This date represents a change of more than 30 calendar days from the anniversary of the previous annual meeting, triggering specific deadlines for shareholder communications.
Guidance, Outlook, and Corporate Actions
- Annual Meeting Date: November 12, 2026.
- Proposal Deadline: Stockholder proposals under Rule 14a-8 must be received by September 24, 2026.
- Director Nominations: Notices for director nominations under the Bylaws must be received by September 24, 2026.
- Universal Proxy Rules: Notices for proxy solicitations under Rule 14a-19 must be received by September 24, 2026.
- Future Disclosure: Specific details regarding the time, location, and matters to be voted on will be published in the upcoming proxy statement.
Key Facts for Investor Verification
- Verify the exact time and location of the Annual Meeting once the proxy statement is released.
- Confirm the September 24, 2026 deadline for submitting Rule 14a-8 proposals and director nominations.
- Review the Company's Amended and Restated Bylaws for specific formatting and content requirements for shareholder proposals.
- Note that the filing does not contain financial updates; refer to the most recent 10-K or 10-Q for financial status.